424 related articles for article (PubMed ID: 35803084)
41. A systematic literature review to examine the considerations around pregnancy in women of child-bearing age with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) or aquaporin 4 neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Leite MI; Panahloo Z; Harrison N; Palace J
Mult Scler Relat Disord; 2023 Jul; 75():104760. PubMed ID: 37224631
[TBL] [Abstract][Full Text] [Related]
42. Estimated prevalence of AQP4 positive neuromyelitis optica spectrum disorder and MOG antibody associated disease in São Paulo, Brazil.
Silva GD; Apóstolos-Pereira SL; Callegaro D
Mult Scler Relat Disord; 2023 Feb; 70():104488. PubMed ID: 36610359
[TBL] [Abstract][Full Text] [Related]
43. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
[TBL] [Abstract][Full Text] [Related]
44. Impact of COVID-19 public health measures on myelin oligodendrocyte glycoprotein IgG-associated disorders in children.
Kaseka ML; Ly M; Yea C; Longoni G; Yeh EA
Mult Scler Relat Disord; 2021 Nov; 56():103286. PubMed ID: 34627003
[TBL] [Abstract][Full Text] [Related]
45. Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: Case report and systematic review.
Anamnart C; Tisavipat N; Owattanapanich W; Apiwattanakul M; Savangned P; Prayoonwiwat N; Siritho S; Rattanathamsakul N; Jitprapaikulsan J
Mult Scler Relat Disord; 2022 Feb; 58():103414. PubMed ID: 35216789
[TBL] [Abstract][Full Text] [Related]
46. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
[TBL] [Abstract][Full Text] [Related]
47. COVID-19 vaccine response in Neuromyelitis Optica Spectrum Disorder.
Baba C; Kaya E; Ozcelik S; Ozdogar AT; Samadzade U; Cevik S; Calıskan C; Dogan Y; Ozakbas S
Clin Neurol Neurosurg; 2024 Mar; 238():108152. PubMed ID: 38382130
[TBL] [Abstract][Full Text] [Related]
48. Brighter spotty lesions on spinal MRI help differentiate AQP4 antibody-positive NMOSD from MOGAD.
Hyun JW; Lee HL; Park J; Kim J; Min JH; Kim BJ; Kim SW; Shin HY; Huh SY; Kim W; Seo JW; Kim KH; Kim SH; Kim HJ
Mult Scler; 2022 May; 28(6):989-992. PubMed ID: 34865555
[TBL] [Abstract][Full Text] [Related]
49. Cerebral enhancement in MOG antibody-associated disease.
Elsbernd P; Cacciaguerra L; Krecke KN; Chen JJ; Gritsch D; Lopez-Chiriboga AS; Sechi E; Redenbaugh V; Morris PP; Carter JL; Wingerchuk DM; Tillema JM; Valencia-Sanchez C; Thakolwiboon S; Pittock SJ; Flanagan EP
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):14-18. PubMed ID: 37221051
[TBL] [Abstract][Full Text] [Related]
50. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
51. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
[TBL] [Abstract][Full Text] [Related]
52. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C
J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
Schreiner T; Wilson-Murphy M; Mendelt-Tillema J; Waltz M; Codden R; Benson L; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Ness J; Rensel M; Roalstad S; Rodriguez M; Rose J; Shukla N; Waubant E; Wheeler Y; Casper TC; Chitnis T
Mult Scler; 2023 Apr; 29(4-5):576-584. PubMed ID: 36960480
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Louapre C; Maillart E; Papeix C; Zeidan S; Biotti D; Lepine Z; Wahab A; Zedet M; Labauge P; Tilikete C; Pique J; Tourbah A; Mathey G; Dimitri Boulos D; Branger P; Kremer LD; Marignier R; Collongues N; De Seze J
Eur J Neurol; 2021 Oct; 28(10):3461-3466. PubMed ID: 33103295
[TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
Spagni G; Sun B; Monte G; Sechi E; Iorio R; Evoli A; Damato V
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):62-69. PubMed ID: 36283808
[TBL] [Abstract][Full Text] [Related]
57. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW; Bütow F; Tkachenko D; Ayzenberg I; Pakeerathan T; Hellwig K; Klotz L; Häußler V; Stellmann JP; Warnke C; Goereci Y; Etgen T; Luessi F; Bronzlik P; Gingele S; Lauenstein AS; Kleiter I; Rommer PS; Paul F; Bellmann-Strobl J; Duchow A; Then Bergh F; Pul R; Walter A; Pellkofer H; Kümpfel T; Pompsch M; Kraemer M; Albrecht P; Aktas O; Ringelstein M; Senel M; Giglhuber K; Berthele A; Jarius S; Wildemann B; Trebst C;
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36693760
[TBL] [Abstract][Full Text] [Related]
58. Towards imaging criteria that best differentiate MS from NMOSD and MOGAD: Large multi-ethnic population and different clinical scenarios.
Carnero Contentti E; Rojas JI; Criniti J; Lopez PA; Daccach Marques V; Soto de Castillo I; Tkachuk V; Marrodan M; Correale J; Farez MF; Kim HJ; Hyun JW; Messina S; Mariano R; Rocca MA; Cacciaguerra L; Filippi M; Palace J; Juryńczyk M
Mult Scler Relat Disord; 2022 May; 61():103778. PubMed ID: 35452969
[TBL] [Abstract][Full Text] [Related]
59. Central nervous system (CNS) inflammatory demyelinating diseases (IDDs) associated with COVID-19: A case series and review.
Feizi P; Sharma K; Pasham SR; Nirwan L; Joseph J; Jaiswal S; Sriwastava S
J Neuroimmunol; 2022 Oct; 371():577939. PubMed ID: 35939945
[TBL] [Abstract][Full Text] [Related]
60. Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults.
Duan Z; Feng J
J Clin Neurosci; 2022 Jul; 101():89-93. PubMed ID: 35569419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
